Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Half of all drugs that received accelerated approval by the FDA from 2009-2013 failed to complete required post-approval studies within three years of going on the market, according to a study published Tuesday in JAMA. Another study, also in JAMA, found that less than half of all high-risk medical device modifications underwent rigorous testing before entering the market.
Since 1992, drugs that treat serious illnesses have had the option of fast-tracking their FDA approval. Instead of completing rigorous clinical trials that can take years, the FDA would allow companies to put promising drugs on the market on the condition that they continue to conduct studies that prove that the drugs actually work.
What they did: The first study looked at 38 trials for 22 drugs, and found that only 19 of those trials were completed within three years. The ones that were finished were frequently not as rigorous as the studies that would have been required had the drug been approved via normal channels. There was also evidence of missing or lost data and selection bias.
It's not all bad, notes STAT's Damien Garde, who writes that a study published this week in Health Affairs concludes "that the agency is consistently singling out the most promising therapies [for] speedy review."